Oxidative Stress Markers and C-Reactive Protein Are Related to Severity of Heart Failure in Patients with Dilated Cardiomyopathy

Table 1

Pharmacological treatment with division into groups depending on NYHA class.

	All DCM; (D)	D (%)	NYHA I-II; (A)	A (%)	NYHA III-IV; (B)	B (%)
BB	103	94.50	61	92.42	42	97.67	NS
ACE-I	101	92.66	62	93.94	39	90.70	NS
ARB	39	35.78	26	39.39	13	30.23	NS
MRA	99	90.83	59	89.39	40	93.02	NS
AM	15	13.76	9	13.64	6	13.95	NS
LD	66	60.55	31	46.97	35	81.40
TD	20	18.35	14	21.21	6	13.95	NS
OAK	49	44.95	24	36.36	25	58.14
DIG	69	63.30	39	59.09	30	69.77	NS

BB: -blocker; ACE-I: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; MRA: mineralocorticoid receptor antagonist; AM: amiodarone; LD: loop diuretic; TD: thiazide diuretic; OAK: oral anticoagulation; DIG: digitalis.